Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ENLV
- Price
- 1.10
- Stock movement down
- -0.01 (-0.90%)
- Company name
- Enlivex Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 261.12M
- Ent value
- 260.38M
- Price/Sales
- -
- Price/Book
- 14.94
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -39.02%
- 1 year return (CAGR)
- 5.77%
- 3 year return (CAGR)
- -37.00%
- 5 year return (CAGR)
- -46.02%
- 10 year return (CAGR)
- -37.28%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENLV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 14.94 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 237.38M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.51 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -256.00K |
| Operating income (TTM) | -14.04M |
| Net income (TTM) | -12.70M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | -0.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.20M |
| Net receivables | 567.00K |
| Total current assets | 19.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.78M |
| Total assets | 20.94M |
| Accounts payable | 375.00K |
| Short/Current long term debt | 701.00K |
| Total current liabilities | 3.03M |
| Total liabilities | 3.46M |
| Shareholder's equity | 17.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.23M |
| Capital expenditures (TTM) | 97.55K |
| Free cash flow (TTM) | -12.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -72.66% |
| Return on Assets | -60.66% |
| Return on Invested Capital | -71.53% |
| Cash Return on Invested Capital | -69.42% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.09 |
| Daily high | 1.12 |
| Daily low | 1.08 |
| Daily Volume | 130K |
| All-time high | 391.60 |
| 1y analyst estimate | 13.00 |
| Beta | 1.64 |
| EPS (TTM) | -0.53 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ENLV | S&P500 | |
| Current price drop from All-time high | -99.72% | -1.82% |
| Highest price drop | -99.83% | -56.47% |
| Date of highest drop | 30 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -88.28% | -10.84% |
| Avg time to new high | 264 days | 12 days |
| Max time to new high | 2885 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
261.12M
Marketcap category
Small-cap
Description
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Oren Hershkovitz
Country
USA
City
Nes-Ziona
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page